Publications by authors named "Debora Fumagalli"

52Publications

Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.

Anticancer Drugs 2019 09;30(8):866-872

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, and Peking Union Medical College, Beijing.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CAD.0000000000000808DOI Listing
September 2019

Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.

Ther Adv Med Oncol 2019 25;11:1758835919827714. Epub 2019 Feb 25.

Institut Jules Bordet, Université Libre de Bruxelles, Boulevard de Waterloo 121, 1000 Bruxelles, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1758835919827714DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6393951PMC
February 2019

Feasibility of developing reliable gene expression modules from FFPE derived RNA profiled on Affymetrix arrays.

PLoS One 2018 31;13(8):e0203346. Epub 2018 Aug 31.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0203346PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6118369PMC
February 2019

Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data.

J Clin Oncol 2018 04 22;36(10):981-990. Epub 2018 Feb 22.

Dimitrios Zardavas and Debora Fumagalli, Breast International Group; Christos Sotiriou, Université Libre de Bruxelles, Brussels, Belgium; Luc te Marvelde and Roger L. Milne, Cancer Council; Roger L. Milne and Sherene Loi, University of Melbourne, Melbourne; Barry Iacopetta, University of Western Australia, Western Australia; Sandra O'Toole and Elena Lopez-Knowles, Garvan Institute of Medical Research, Darlinghurst, Australia; George Fountzilas and Vassiliki Kotoula, Hellenic Foundation for Cancer Research/Aristotle University of Thessaloniki, Thessaloniki; Evangelia Razis, Hygeia Hospital; George Papaxoinis, Hippokration Hospital, Athens, Greece; Heikki Joensuu, Helsinki University Hospital and University of Helsinki, Helsinki, Finland; Mary Ellen Moynahan, Memorial Sloan Kettering Cancer Center, New York, NY; Bryan T. Hennessy, Beaumont Hospital and Royal College of Surgeons, Dublin, Ireland; Ivan Bieche, Curie Institut, Paris; Thomas Bachelot, Centre de Recherche en Cancérologie de Lyon, Lyon; Stefan Michiels, Gustave Roussy and Inserm, Univ. Paris-Sud, Univ. Paris-Saclay, Villejuif, France; Lao H. Saal, Lund University, Lund; Olle Stal, Qing Wang, and Gizeh Perez-Tenorio, Linköping University, Linköping, Sweden; Jeanette Dupont Jensen, University of Southern Denmark, on behalf of the Danish Breast Cancer Cooperative Group, Odense, Denmark; Elena Lopez-Knowles, Royal Marsden NHS Trust and Institute of Cancer Research, London; Daniel W. Rea, University of Birmingham, Birmingham, United Kingdom; Mattia Barbaraeschi, Santa Chiara Hospital, Trento, Italy; Shinzaburo Noguchi, Osaka University, Osaka Japan; Hatem A. Azim Jr, American University of Beirut (AUB), Beirut, Lebanon; Enrique Lerma, Universitat Autònoma de Barcelona, Barcelona, Spain; Cornelis J.H. can de Velde, Leiden University Medical Center, Leiden, the Netherlands; Vicky Sabine, University of Guelph, Guelph; John M.S. Bartlett, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2017.74.8301DOI Listing
April 2018

Genomic hotspots but few recurrent fusion genes in breast cancer.

Genes Chromosomes Cancer 2018 07 22;57(7):331-338. Epub 2018 Mar 22.

IRIBHM, Université Libre de Bruxelles (ULB), 808 route de Lennik, Brussels, 1070, Belgium.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1002/gcc.22533
Publisher Site
http://dx.doi.org/10.1002/gcc.22533DOI Listing
July 2018

Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.

J Clin Oncol 2017 May 13;35(13):1421-1429. Epub 2017 Mar 13.

Amir Sonnenblick, Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Dominique Agbor-Tarh and Ian Bradbury, Frontier Science, Kingussie, United Kingdom; Serena Di Cosimo Fondazione IRCCS, Istituto Nazionale dei Tumori, Milan, Italy; Hatem A. Azim Jr, Martine Piccart-Gebhart and Evandro de Azambuja, Université Libre de Bruxelles; Debora Fumagalli, Breast International Group, Brussels, Belgium; Severine Sarp, Novartis Pharma AG, Basel, Switzerland; Antonio C. Wolff, Johns Hopkins School of Medicine, Baltimore, MD; Lyndsay Harris, Case Western Reserve University School of Medicine, Cleveland, OH; Julie Gralow, Seattle Cancer Care Alliance, Seattle, WA; Alvaro Moreno-Aspitia, Mayo Clinic, Jacksonville, FL; Michael Andersson, Rigshospitalet University Hospital Copenhagen, Denmark; Judith Kroep, Leiden University Medical Center, Leiden, the Netherlands; Tanja Cufer, University Clinic Golnik Medical Faculty, Ljubljana, Slovenia; Sergio D. Simon, Hospital Israelita Albert Einstein; Sergio D. Simon, Grupo Brasileiro de Estudos do Cancer de Mama, São Paulo, Brazil; Pamela Salman, Fundación Arturo López Pérez, Santiago, Chile; Masakazu Toi, Kyoto University, Kyoto, Japan; Maccon Keane, University Hospital Galway, Galway; and Maccon Keane, Cancer Trials Ireland, Dublin, Ireland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.69.7722DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5455460PMC
May 2017

The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data.

Clin Cancer Res 2017 Jun 9;23(11):2702-2712. Epub 2016 Nov 9.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brusells, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-16-0979DOI Listing
June 2017

Genomic Characterization of Primary Invasive Lobular Breast Cancer.

J Clin Oncol 2016 06 29;34(16):1872-81. Epub 2016 Feb 29.

Christine Desmedt, Gabriele Zoppoli, Denis Larsimont, Debora Fumagalli, David Brown, Françoise Rothé, Delphine Vincent, Naima Kheddoumi, Ghizlane Rouas, Samira Majjaj, Sylvain Brohée, Roberto Salgado, Martine Piccart-Gebhart, and Christos Sotiriou, Institut Jules Bordet; Christine Galant, Cliniques Universitaires Saint Luc, Brussels; Peter Van Loo, University of Leuven; Thomas Van Brussel and Diether Lambrechts, VIB Vesalius Research Center, Leuven, Belgium; Gabriele Zoppoli, University of Genoa and Istituto di Ricerca a Carattere Clinico-Scientifico San Martino-National Cancer Institute, Genoa; Giancarlo Pruneri, Patrick Maisonneuve, and Giuseppe Viale, European Institute of Oncology; Marco Fornili and Elia Biganzoli, University of Milan, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale Tumori, Milan, Italy; Gunes Gundem and Peter J. Campbell, Wellcome Trust Sanger Institute, Cambridgeshire; Peter Van Loo, The Francis Crick Institute, London, United Kingdom; Ron Bose, Washington University School of Medicine, St Louis, MO; Otto Metzger, Dana-Farber Cancer Institute, Boston, MA; and François Bertucci, Institut Paoli-Calmettes, Marseille, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2015.64.0334DOI Listing
June 2016

No significant viral transcription detected in whole breast cancer transcriptomes.

BMC Cancer 2015 Mar 18;15:147. Epub 2015 Mar 18.

IRIBHM - Université Libre de Bruxelles, ULB, Campus Erasme CP602, 808 route de Lennik, 1070, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-015-1176-2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4374178PMC
March 2015

PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer.

J Clin Oncol 2015 Apr 5;33(12):1334-9. Epub 2015 Jan 5.

Ian J. Majewski, Lorenza Mittempergher, Astrid J. Bosma, and René Bernards, The Netherlands Cancer Institute, Amsterdam, the Netherlands; Paolo Nuciforo, Jose Jimenez, Claudia Aura, Ludmila Prudkin, Maria Carmen Díaz-Delgado, Vall D'Hebron Institute of Oncology; Lorena de la Peña, Spanish Breast Cancer Cooperative Group SOLTI, Barcelona, Spain; Holger Eidtmann, University Hospital Kiel, Kiel; Nadia Harbeck, University of Munich, Munich, Germany; Eileen Holmes, Frontier Science Scotland, Kincraig, United Kingdom; Christos Sotiriou, Debora Fumagalli, and Martine Piccart-Gebhart, Institut Jules Bordet, Université Libre de Bruxelles; Evandro de Azambuja, BrEAST Data Center and Institut Jules Bordet, Brussels, Belgium; Sherene Loi, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia; Catherine Ellis, GlaxoSmithKline, Collegeville, PA; and Nikolaus Schultz and José Baselga, Memorial Sloan-Kettering Cancer Center, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.55.2158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5087318PMC
April 2015

New strategies in breast cancer: the significance of molecular subtypes in systemic adjuvant treatment for small T1a,bN0M0 tumors.

Clin Cancer Res 2014 Dec 21;20(24):6242-6. Epub 2014 Oct 21.

BrEAST Data Center, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-14-1086DOI Listing
December 2014

Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?

Cancer Treat Rev 2014 Oct 12;40(9):1089-95. Epub 2014 Aug 12.

BrEAST Data Centre, Department of Medicine, Institut Jules Bordet, Université Libre de Bruxelles, Belgium. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ctrv.2014.07.005DOI Listing
October 2014

Luminal B breast cancer: molecular characterization, clinical management, and future perspectives.

J Clin Oncol 2014 Sep 21;32(25):2794-803. Epub 2014 Jul 21.

Felipe Ades, Lina Pugliano, Debora Fumagalli, Evandro de Azambuja, Christos Sotiriou, and Martine Piccart, Institut Jules Bordet, Université Libre de Bruxelles; Dimitrios Zardavas, Breast International Group, Brussels, Belgium; Ivana Bozovic-Spasojevic, Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; and Giuseppe Viale, European Institute of Oncology, University of Milan, Milan, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.54.1870DOI Listing
September 2014

Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31.

J Natl Cancer Inst 2013 Dec 21;105(23):1782-8. Epub 2013 Nov 21.

Affiliations of authors: National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA (J-HJ, HB, PR, LF, EHR, SMS, EPM, DLW, CEG,Jr, JPC, NW, SP); Division of Pathology, NSABP (KLP-G, CK, NT, PGG, DF, YT, OLB, AL, S-IK, MLR, MYR, NLB, S-RK, ZDH); Department of Biostatistics, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA (J-HJ, HB, JPC); PhenoPath Laboratories, PLLC, Seattle, WA (LCG); Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX (NS); Department of Pathology, University Medical Center Hamburg-Eppendorf, University Cancer Center, Hamburg, Germany (EB); Department of Pathology, Catholic University of Korea, Seoul, Republic of South Korea (AL); University of Pittsburgh Cancer Institute, Pittsburgh, PA (PR); Department of Oncology, Kaiser Permanente, Northern California, Vallejo, CA (LF); Department of Internal Medicine, Markey Cancer Center, University of Kentucky, Lexington, KY (EHR); Department of Medicine, Washington Cancer Institute, MedStar Washington Hospital Center, Washington, DC (SMS); Department of Surgery, MD Anderson Cancer Center Orlando, Orlando, FL (EPM); Department of Medicine, Virginia Commonwealth University, Richmond, VA (CEG, Jr); Department of Surgery, Allegheny Cancer Center at Allegheny General Hospital, Pittsburgh, PA (DLW, NW); Department of Biomedical Science, Severance Biomedical Science Institute, and Department of Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea (SP).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt321DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3848987PMC
December 2013

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer.

J Natl Cancer Inst 2013 Jul 5;105(13):960-7. Epub 2013 Jun 5.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djt121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699437PMC
July 2013

Molecular biology in breast cancer: should molecular classifiers be assessed by conventional tools or by gene expression arrays?

Crit Rev Oncol Hematol 2012 Dec 7;84 Suppl 1:e58-69. Epub 2012 Sep 7.

Breast Cancer Translational Research Unit, Jules Bordet Institute, Universite Libre de Bruxelles, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.critrevonc.2012.08.003DOI Listing
December 2012

Gene profiling assay and application: the predictive role in primary therapy.

J Natl Cancer Inst Monogr 2011 ;2011(43):124-7

Breast Cancer Translational Research Laboratory, Faculty of Medicine, Université Libre de Bruxelles, Institut Jules Bordet, Bruxelles 1000, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jncimonographs/lgr040DOI Listing
March 2012

Unravelling the epigenomic dimension of breast cancers.

Curr Opin Oncol 2011 Nov;23(6):559-65

Laboratory of Cancer Epigenetics, Université Libre de Bruxelles, Faculty of Medicine, Brussels, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0b013e32834bd481DOI Listing
November 2011

Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection.

Onco Targets Ther 2010 Dec 17;4:1-11. Epub 2010 Dec 17.

Breast Cancer Translational Research Laboratory, Institut Jules Bordet, Université Libre de Bruxelles, Brussels;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/OTT.S10155DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3084302PMC
December 2010

CD44+ CD24-/low phenotype and resistance to trastuzumab in HER2-positive breast cancer cell lines.

Pharmacogenomics 2011 Jan;12(1):12-3

Laboratoire JC Heuson de Recherche Translationnelle en Cancérologie Mammaire, Université Libre de Bruxelles, Boulevard de Waterloo, 121-1000 Bruxelles, Belgium.

View Article

Download full-text PDF

Source
January 2011

Gene-expression changes over time in a tamoxifen-treated breast cancer xenograft model.

Pharmacogenomics 2011 Jan;12(1):11

Laboratoire JC Heuson de Recherche Translationnelle en Cancérologie Mammaire, Université Libre de Bruxelles, Boulevard de Waterloo, 121-1000 Bruxelles, Belgium.

View Article

Download full-text PDF

Source
January 2011

A time series evaluation of the in vivo effect of letrozole on gene expression in breast cancer.

Pharmacogenomics 2011 Jan;12(1):10

Laboratoire JC Heuson de Recherche Translationnelle en Cancérologie Mammaire, Université Libre de Bruxelles, Boulevard de Waterloo, 121-1000 Bruxelles, Belgium.

View Article

Download full-text PDF

Source
January 2011

Proteomic changes associated with breast cancer progression in the MCF10AT model.

Pharmacogenomics 2011 Jan;12(1):9-10

Laboratoire JC Heuson de Recherche Translationnelle en Cancérologie Mammaire, Université Libre de Bruxelles, Boulevard de Waterloo, 121-1000 Bruxelles, Belgium.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.10.194DOI Listing
January 2011

Molecular profiling: moving away from tumor philately.

Sci Transl Med 2010 Sep;2(47):47ps43

Molecular Pathology Laboratory, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, UK.

View Article

Download full-text PDF

Source
http://stm.sciencemag.org/cgi/doi/10.1126/scitranslmed.30013
Publisher Site
http://dx.doi.org/10.1126/scitranslmed.3001329DOI Listing
September 2010

An ideal prognostic test for estrogen receptor-positive breast cancer?

J Clin Oncol 2008 Sep 4;26(25):4058-9. Epub 2008 Aug 4.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2008.16.7528DOI Listing
September 2008